Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF) Social Stream
CAN-FITE BIOPHARMA LTD (CANF) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering CAN-FITE BIOPHARMA LTD.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-09-13 | 2 | $50 | $50 | $50 | $2.49 | 1908.03% |
| 2022-11-29 | 2 | $5 | $5 | $5 | $2.49 | 100.8% |
| 2022-12-12 | 2 | $8 | $5 | $6.5 | $2.49 | 161.04% |
| 2023-01-27 | 2 | $34 | $34 | $34 | $2.49 | 1265.46% |
| 2023-06-02 | 2 | $34 | $6 | $20 | $2.49 | 703.21% |
| 2023-08-31 | 2 | $34 | $6 | $17.333 | $2.49 | 596.1% |
The Trend in the Analyst Price Target
Over the past 43 months, CANF's average price target has gone up $10.33.
CANF reports an average of 666.25% for its upside potential over the past 39 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-27 | 2 | 34 | 34 | 34.000 | 4.070 | 735.38% |
| 2023-05-30 | 2 | 34 | 6 | 20.000 | 2.465 | 711.36% |
| 2023-06-02 | 2 | 34 | 6 | 20.000 | 2.790 | 616.85% |
| 2023-07-24 | 2 | 34 | 6 | 17.333 | 3.030 | 472.05% |
| 2023-08-31 | 2 | 34 | 6 | 17.333 | 2.940 | 489.56% |
CANF Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 2 | 0 | 0 | 0 | 0 | 2 |
The Trend in the Broker Recommendations
CANF's average broker recommendation rating improved by 0 over the prior 24 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- CANF has a greater number of analysts covering the stock than 18.36% of all US stocks.
- CAN-FITE BIOPHARMA LTD's variance in analysts' estimates is lower than -146.87% of all US stocks.
- In the context of stocks in the micro market cap category, CAN-FITE BIOPHARMA LTD's average analyst price target is higher than 393.83% of them.
- In the context of Healthcare stocks, CAN-FITE BIOPHARMA LTD's upside potential (average analyst target price relative to current price) is higher than 451.32% of them.
In the Pharmaceutical Products industry, BLRX, GLMD, and EDSA are the three stocks most similar to CAN-FITE BIOPHARMA LTD regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Make investment decisions regarding CANF using the data that counts. Try POWR Ratings for free.